FDA Regulatory Uncertainty Calls for Strategic Decision-Making by Drug Developers

April 7, 2025, 8:56 am

≫ Next: HHS Signals GRAS Reform: How Food Manufacturers Can Prepare Now

≪ Previous: Key Considerations for Foreign Clinical Trials When Looking Abroad for Product Development

The recent reductions in the US Food and Drug Administration’s workforce are poised to have a substantial impact on drug and biologic development programs. This LawFlash discusses strategies to optimize interactions with the Agency and keep development programs on track....
By:

↧